FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:GPR89B-CAPN2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: GPR89B-CAPN2
FusionPDB ID: 34476
FusionGDB2.0 ID: 34476
HgeneTgene
Gene symbol

GPR89B

CAPN2

Gene ID

653519

824

Gene nameG protein-coupled receptor 89Acalpain 2
SynonymsGPHR|GPR89|GPR89B|SH120|UNQ192CANP2|CANPL2|CANPml|mCANP
Cytomap

1q21.1

1q41

Type of geneprotein-codingprotein-coding
DescriptionGolgi pH regulator Aprotein GPR89putative MAPK-activating protein PM01putative NF-kappa-B-activating protein 90calpain-2 catalytic subunitCANP 2M-calpaincalcium-activated neutral proteinase 2calpain 2, (m/II) large subunitcalpain 2, large [catalytic] subunitcalpain 2, large subunitcalpain M-typecalpain, large polypeptide L2millimolar-calpain
Modification date2020031320200313
UniProtAcc

P0CG08

Main function of 5'-partner protein: FUNCTION: Voltage dependent anion channel required for acidification and functions of the Golgi apparatus that may function in counter-ion conductance (PubMed:18794847). Plays a role in lymphocyte development, probably by acting as a RABL3 effector in hematopoietic cells (By similarity). {ECO:0000250|UniProtKB:Q8BS95, ECO:0000269|PubMed:18794847}.

P17655

Main function of 5'-partner protein: FUNCTION: Calcium-regulated non-lysosomal thiol-protease which catalyzes limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction. Proteolytically cleaves MYOC at 'Arg-226' (PubMed:17650508). Proteolytically cleaves CPEB3 following neuronal stimulation which abolishes CPEB3 translational repressor activity, leading to translation of CPEB3 target mRNAs (By similarity). {ECO:0000250|UniProtKB:O08529, ECO:0000269|PubMed:17650508}.
Ensembl transtripts involved in fusion geneENST idsENST00000488603, ENST00000314163, 
ENST00000295006, ENST00000433674, 
ENST00000474026, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score6 X 3 X 4=7211 X 7 X 7=539
# samples 611
** MAII scorelog2(6/72*10)=-0.263034405833794
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(11/539*10)=-2.29278174922785
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: GPR89B [Title/Abstract] AND CAPN2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: GPR89B [Title/Abstract] AND CAPN2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)GPR89B(147460753)-CAPN2(223946971), # samples:1
Anticipated loss of major functional domain due to fusion event.GPR89B-CAPN2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
GPR89B-CAPN2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
GPR89B-CAPN2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
GPR89B-CAPN2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneGPR89B

GO:0051452

intracellular pH reduction

18794847

TgeneCAPN2

GO:0051603

proteolysis involved in cellular protein catabolic process

12150984



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:147460753/chr1:223946971)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across GPR89B (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across CAPN2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000314163GPR89Bchr1147460753+ENST00000433674CAPN2chr1223946971+31841239752024649
ENST00000314163GPR89Bchr1147460753+ENST00000295006CAPN2chr1223946971+31861239752024649

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000314163ENST00000433674GPR89Bchr1147460753+CAPN2chr1223946971+0.001897420.9981026
ENST00000314163ENST00000295006GPR89Bchr1147460753+CAPN2chr1223946971+0.0018978450.9981021

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for GPR89B-CAPN2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
GPR89Bchr1147460753CAPN2chr12239469711239388VTSIRGLLITLTKLSGQTNIHLSKNF

Top

Potential FusionNeoAntigen Information of GPR89B-CAPN2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
GPR89B-CAPN2_147460753_223946971.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
GPR89B-CAPN2chr1147460753chr12239469711239HLA-A02:13GLLITLTKL0.89330.5424514
GPR89B-CAPN2chr1147460753chr12239469711239HLA-A02:04GLLITLTKL0.85480.5122514

Top

Potential FusionNeoAntigen Information of GPR89B-CAPN2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
GPR89B-CAPN2_147460753_223946971.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-0802RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-0804RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-0804IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-0809RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-0813RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-0820RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-0820IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-0821RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-0824RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-0824IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-0828RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-0828IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-0828SIRGLLITLTKLSGQ217
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-0831RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-0831IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-0831SIRGLLITLTKLSGQ217
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1101RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1101IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1104RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1104IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1105RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1105IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1106RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1106IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1108RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1108IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1109RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1109IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1110RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1110IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1112RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1112IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1113RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1113IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1115RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1115IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1118RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1118IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1118SIRGLLITLTKLSGQ217
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1119RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1119IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1124RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1124IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1125RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1125IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1127RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1127IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1128RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1128IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1129RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1129IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1131RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1131IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1132RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1132IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1133RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1133IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1134RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1134IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1135RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1135IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1137RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1138RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1138IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1139RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1139IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1142RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1142IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1142SIRGLLITLTKLSGQ217
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1143RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1143IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1144RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1144IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1145RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1146RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1146IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1147RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1147IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1149RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1149IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1150RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1150IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1151RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1151IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1154RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1156RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1156IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1157RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1157IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1158RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1158IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1160RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1160IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1161RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1161IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1162RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1162IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1164RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1166RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1166IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1167RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1167IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1167SIRGLLITLTKLSGQ217
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1172RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1174RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1174IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1175RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1175IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1177RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1177IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1178RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1178IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1180RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1181RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1183RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1183IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1184RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1184IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1184SIRGLLITLTKLSGQ217
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1187RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1188RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1188IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1190RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1190IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1191RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1191IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1192RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1192IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1194RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1194IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1195RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1195IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1196RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1196IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1204RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1204IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1209RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1209IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1305RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1305IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1306RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1306IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1306SIRGLLITLTKLSGQ217
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1307RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1311RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1311IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1314RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1314IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1318RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1318IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1326RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1342RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1342IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1344RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1344IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1347RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1350RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1350IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1356RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1356IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1360RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1362RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1362IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1382RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1382IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1406RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1406IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1409RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1412RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1415RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1415IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1417RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1417IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1420RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1420IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1421RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1427RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1429RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1430RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1434RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1434IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1452RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1452IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1474RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1480RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1480IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1481RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1483RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1483IRGLLITLTKLSGQT318
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1484RGLLITLTKLSGQTN419
GPR89B-CAPN2chr1147460753chr12239469711239DRB1-1484IRGLLITLTKLSGQT318

Top

Fusion breakpoint peptide structures of GPR89B-CAPN2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
5228LLITLTKLSGQTNIGPR89BCAPN2chr1147460753chr12239469711239

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of GPR89B-CAPN2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN5228LLITLTKLSGQTNI-7.9962-8.1096
HLA-B14:023BVN5228LLITLTKLSGQTNI-5.70842-6.74372
HLA-B52:013W395228LLITLTKLSGQTNI-6.83737-6.95077
HLA-B52:013W395228LLITLTKLSGQTNI-4.4836-5.5189
HLA-A11:014UQ25228LLITLTKLSGQTNI-10.0067-10.1201
HLA-A11:014UQ25228LLITLTKLSGQTNI-9.03915-10.0745
HLA-A24:025HGA5228LLITLTKLSGQTNI-6.56204-6.67544
HLA-A24:025HGA5228LLITLTKLSGQTNI-5.42271-6.45801
HLA-B44:053DX85228LLITLTKLSGQTNI-7.85648-8.89178
HLA-B44:053DX85228LLITLTKLSGQTNI-5.3978-5.5112
HLA-A02:016TDR5228LLITLTKLSGQTNI-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of GPR89B-CAPN2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
GPR89B-CAPN2chr1147460753chr1223946971514GLLITLTKLGGATTGCTGATCACTCTTACCAAGTTA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
GPR89B-CAPN2chr1147460753chr1223946971217SIRGLLITLTKLSGQTCCATCAGAGGATTGCTGATCACTCTTACCAAGTTAAGTGGGCAG
GPR89B-CAPN2chr1147460753chr1223946971318IRGLLITLTKLSGQTATCAGAGGATTGCTGATCACTCTTACCAAGTTAAGTGGGCAGACC
GPR89B-CAPN2chr1147460753chr1223946971419RGLLITLTKLSGQTNAGAGGATTGCTGATCACTCTTACCAAGTTAAGTGGGCAGACCAAC

Top

Information of the samples that have these potential fusion neoantigens of GPR89B-CAPN2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
Non-CancerGPR89B-CAPN2chr1147460753ENST00000314163chr1223946971ENST0000029500661N

Top

Potential target of CAR-T therapy development for GPR89B-CAPN2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneGPR89Bchr1:147460753chr1:223946971ENST00000314163+1214114_134365456.0TransmembraneHelical
HgeneGPR89Bchr1:147460753chr1:223946971ENST00000314163+1214150_170365456.0TransmembraneHelical
HgeneGPR89Bchr1:147460753chr1:223946971ENST00000314163+1214290_310365456.0TransmembraneHelical
HgeneGPR89Bchr1:147460753chr1:223946971ENST00000314163+1214343_363365456.0TransmembraneHelical
HgeneGPR89Bchr1:147460753chr1:223946971ENST00000314163+121446_66365456.0TransmembraneHelical
HgeneGPR89Bchr1:147460753chr1:223946971ENST00000314163+12145_25365456.0TransmembraneHelical
HgeneGPR89Bchr1:147460753chr1:223946971ENST00000314163+121479_99365456.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to GPR89B-CAPN2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to GPR89B-CAPN2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource